This second paper to be published in the Wounds veterinary wounds department [Cupp MS, Swaim SF, Amalsadvala T, et al. Use of a recombinant vasoactive protein (rSVEP) to enhance healing of surgically created wounds. WOUNDS 2004;16(3):85–90] provides a good example of the way in which research into the management of animal wounds mirrors that of research into problems associated with the management of wounds in humans.

The authors describe the validation under experimental conditions of an innovative hypothesis illustrating the improvement in wound healing of surgically created wounds in t

Case Review[1]

A 78-year-old man was referred for a nonhealing ulcer in the left axilla. The patient had a history of lung cancer, which was treated with radiotherapy and chemotherapy three years earlier. About a year ago, he developed an open wound in the left axilla at the site of irradiation. He complained of excessive serous drainage and odor but denied pain. He was cleansing the wound with hydrogen peroxide and leaving it open to the air.

According to the patient, his past medical history was significant for prostate cancer, hyperlipidemia, osteoarthritis, multiple basal cell and s

Introduction

Chronic ulcers of the lower limbs are a major cause of morbidity in European countries, affecting 0.5 to 1.5 percent of the population. Lower-extremity chronic ulcers affect 3 to 5 percent of persons over 60 years of age, with a male:female ratio of 1:2. The most frequent causes are venous failure (70–90% of cases), arterial failure, and metabolic diseases, especially diabetes.[1]

Treatment is usually problematical, requiring a multidisciplinary approach to obtain healing and reduce morbidity. Even with a correct diagnostic-therapeutic approach, about 30 percent of leg ul

Introduction

Nonhealing lower-extremity ulcers are a major cause of physical disability and diminished quality of life. In addition, persistent ulcers have an enormous impact on the use of healthcare resources.

A bioengineered living skin replacement (LSE), (Apligraf®, Organogenesis Inc., Canton, Massachusetts) has been approved by the US Food and Drug Administration (FDA) for use with standard therapeutic compression in the treatment of noninfected partial- and full-thickness skin ulcers due to venous insufficiency of longer than one month’s duration that have not responded adequate

Diabetic Neuropathy Study Using Anodyne Therapy Published in Diabetes Care Demonstrates Reversal of Symptoms

Anodyne® Therapy announces the publication of its second peer-reviewed clinical study to demonstrate restoration of sensation in the feet of patients with diabetes with peripheral neuropathy. This landmark study, conducted at the Joslin Diabetes Center at Morton Plant Hospital in Clearwater, Florida, appeared in the January 2004 issue of Diabetes Care (the Professional Journal of the American Diabetes Association) and is titled, “Restoration of Sensation, Reduced Pain, and Improve